ArticleImmunity2023
Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers.
Open access · greenAbstract read
In one paragraph
Article in Immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- IgM promotes antitumor immunity to a Tn-expressing solid tumor.Journal for immunotherapy of cancer · 2026Article
- Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.Cancer cell · 2026Article
- Isotype-switched antibodies originating from tertiary lymphoid structures can antagonize ovarian cancer progression.iScience · 2026Article
- Defining the rules of engagement: B cells, antibodies and cancer control.Cellular & molecular immunology · 2026Review
- SIRT2-mediated deacetylation of LCK governs the magnitude of T cell receptor signaling.Nature immunology · 2026Article
- Pre-Treatment HBV Activation Modulates Circulating Immune Markers in Hepatocellular Carcinoma Patients Undergoing TACE Plus ICIs and Anti-VEGF Antibodies/TKIs.Cancer management and research · 2026Article
- A B cell-IgA-epithelial axis enhances antitumor immunity and improves outcome in HPV-associated penile squamous cell carcinoma.Nature communications · 2025Article
- Profiling antigen-binding affinity of B cell repertoires in tumors by deep learning predicts immune-checkpoint inhibitor treatment outcomes.Nature cancer · 2025Article
- Polymeric immunoglobulin receptor (pIgR) in cancer progression: a critical role and potential therapeutic target.Apoptosis : an international journal on programmed cell death · 2025Review
- Site-directed antibodies targeting driver mutations of the KRAS protein.New biotechnology · 2025Article
- Breast milk delivery of an engineered dimeric IgA protects neonates against rotavirus.Mucosal immunology · 2025Article
- Enhancing liver fibrosis detection: a novel PIGR-utilizing approach in chronic hepatitis B injury assessment.BMC gastroenterology · 2025Article
- A Comprehensive Methodology for Immortalizing Tumor-Infiltrating B Lymphocytes from Epithelial Cancers.Methods in molecular biology (Clifton, N.J.) · 2025Article
- PIGR predicts good clinical outcomes and plays a tumor suppressor role in the development of breast cancer.Frontiers in oncology · 2025Article
- Design, Production, and Optimization of Antigen-Specific Recombinant Antitumor Dimeric IgA Antibody.Methods in molecular biology (Clifton, N.J.) · 2025Article
- A Bibliometric Analysis of Metabolic Reprogramming in the Tumor Microenvironment From 2003 to 2022.Cancer reports (Hoboken, N.J.) · 2024Review
- Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant.Journal of hematology & oncology · 2024Article
- Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Deubiquitinating enzymes: potential regulators of the tumor microenvironment and implications for immune evasion.Cell communication and signaling : CCS · 2024Review
- Key players of immunosuppression in epithelial malignancies: Tumor-infiltrating myeloid cells and γδ T cells.Cancer reports (Hoboken, N.J.) · 2024Review
Corrections and comments
- Commented on by
Authors and funding
22 authors at 3 institutions in 1 country.
Subir BiswasDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA; Tumor Immunology and Immunotherapy, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India.
Gunjan MandalDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA; Division of Cancer Biology, DBT-Institute of Life Sciences, Bhubaneswar 751023, India.
Carmen M AnadonDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA; Department of Integrated Immunobiology, Duke School of Medicine, Durham, NC 27710, USA; Duke Cancer Institute, Duke School of Medicine, Durham, NC 27710, USA.
Ricardo A ChaurioDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA; Department of Integrated Immunobiology, Duke School of Medicine, Durham, NC 27710, USA; Duke Cancer Institute, Duke School of Medicine, Durham, NC 27710, USA.
Luis U Lopez-BailonDepartment of Integrated Immunobiology, Duke School of Medicine, Durham, NC 27710, USA; Duke Cancer Institute, Duke School of Medicine, Durham, NC 27710, USA.
Mate Z NagyDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Jessica A MineDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA; Department of Integrated Immunobiology, Duke School of Medicine, Durham, NC 27710, USA; Duke Cancer Institute, Duke School of Medicine, Durham, NC 27710, USA.
Kay HänggiDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Kimberly B SprengerDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Patrick InnamaratoDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Carly M HarroDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
John J PowersDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Joseph JohnsonAnalytic Microscopy Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Bin FangProteomics and Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Mostafa EyshaDepartment of Medicine, Duke School of Medicine, Durham, NC 27710, USA.
Xiaolin NanDepartment of Biomedical Engineering, Knight Cancer Institute, and OHSU Center for Spatial Systems Biomedicine (OCSSB), Oregon Health and Science University, Portland, OR 97239, USA.
Roger LiDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Bradford A PerezDepartment of Radiation Therapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Tyler J CurielDepartments of Medicine and Microbiology and Immunology, Dartmouth Geisel School of Medicine, Hanover, NH 03755, USA.
Xiaoqing YuDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Paulo C RodriguezDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Jose R Conejo-GarciaDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA; Department of Integrated Immunobiology, Duke School of Medicine, Durham, NC 27710, USA; Duke Cancer Institute, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: jose.conejo-garcia@duke.edu.
Moffitt Cancer Center · USDuke University · USOregon Health & Science University · US
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MProject 4P01CA250984 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI STEWART, PAUL ALLEN · 2021 to 2025
$10.1MVascular Leukocytes Influence the Tumor MicroenvironmentR01CA124515 · NCI · WISTAR INSTITUTE · PI Jose R Conejo-Garcia · 2007 to 2026
$7.1MRapid Exoproteome Antigen Profiling of antibodies produced in the ovarian cancer microenvironmentU01CA232758 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI CONEJO-GARCIA, JOSE R · 2018 to 2022
$4.1MInitiation and Evolution of the Ovarian Cancer MicroenvironmentR01CA157664 · NCI · WISTAR INSTITUTE · PI CONEJO-GARCIA, JOSE R · 2011 to 2020
$3.8MTargetable epigenetic mechanism driving Cutaneous T cell LymphomaR01CA240434 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI CONEJO-GARCIA, JOSE R, PINILLA, JAVIER · 2019 to 2023
$2.6MPlant-derived extracts regulate immunosuppressive myelopoiesis in Breast cancer patientsR01CA262121 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RODRIGUEZ, PAULO CESAR · 2021 to 2025
$2.1MFunctional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligandsR01CA233512 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RODRIGUEZ, PAULO CESAR · 2019 to 2023
$2.0MMitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumorsR01CA273034 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RODRIGUEZ, PAULO CESAR · 2022 to 2025
$1.9MEffects of Common Polymorphisms in Immune Sensors in Tumor ImmunosurveillanceR01CA178687 · NCI · WISTAR INSTITUTE · PI CONEJO-GARCIA, JOSE R · 2013 to 2017
$1.9MStress Pathways in Tumors Drive Global MDSC Activity and Survival through ChopR01CA184185 · NCI · LSU HEALTH SCIENCES CENTER · PI RODRIGUEZ, PAULO CESAR · 2015 to 2019
$1.8MNCI NIH HHS K08 CA231454NCI NIH HHS K99 CA266947NCI NIH HHS P01 CA250984NCI NIH HHS P30 CA014236NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA124515NCI NIH HHS R01 CA157664NCI NIH HHS R01 CA178687NCI NIH HHS R01 CA184185NCI NIH HHS R01 CA233512NCI NIH HHS R01 CA240434NCI NIH HHS R01 CA262121NCI NIH HHS R01 CA273034NCI NIH HHS R01 CA278907NCI NIH HHS R21 CA132026NCI NIH HHS R21 CA276205NCI NIH HHS U01 CA232758NIGMS NIH HHS R01 GM132322
Abstract
Dimeric IgA (dIgA) can move through cells via the IgA/IgM polymeric immunoglobulin receptor (PIGR), which is expressed mainly on mucosal epithelia. Here, we studied the ability of dIgA to target commonly mutated cytoplasmic oncodrivers. Mutation-specific dIgA, but not IgG, neutralized KRAS
Indexed as
CarcinomaImmunoglobulin ACD8-Positive T-LymphocytesCytoplasmHumansProto-Oncogene Proteins p21(ras)Immunoglobulin AProto-Oncogene Proteins p21(ras)dimeric IgAepithelial malignanciesIDH1IgA transcytosisimmunotherapyintracellular targetingKRASmutation-specific antibodiesPIGRtherapeutic antibody
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.